VBI Vaccines Inc.

VBI Vaccines — Investor Presentation (February 2023)

41 slides from VBI Vaccines's investor presentation, Feb 28, 2023

  1. Slide 1: Corporate Overview February 2023

    Slide 1: Corporate Overview February 2023

    W7 BS \y MIN\\\ VBI Zmyy —— VACCINES ACTIVATING THE POWER WITHIN Corporate Overview February 2023

  2. Slide 2: Forward-Looking & Safe Harbor Statements

    Slide 2: Forward-Looking & Safe Harbor Statements

    i N %, Forward-Looking & Safe Harbor Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forwa

  3. Slide 3: About VBI: Immune to Limitations

    Slide 3: About VBI: Immune to Limitations

    About VBI : Immune to Limitations Ih our inn 5) approach to virus-like particles, our vision is to” Cuplsetisiintits We are a biotechnology company driven by fe A importance of protecting ie and enhancing human life rything Ina ary human immune system to target and overcome significant, aggressive,

  4. Slide 4: The Science of Virus-Like Particles (VLPs)

    Slide 4: The Science of Virus-Like Particles (VLPs)

    The Science of Virus-Like Particles (VLPs) Transforming natural immunity into potent protection and treatment = > _— Virus-Like Particles Enveloped Virus-Like Particles Antigenic Protein Lipid Bilayer - VBI's Proprietary Platform Technology - Sub-unit vaccines with no infectious material <._ _- @VLP

  5. Slide 5: VBI's Portfolio: Both Sides of the Fight

    Slide 5: VBI's Portfolio: Both Sides of the Fight

    VBI's Portfolio : Both Sides of the Fight VBI's broad portfolio is designed to power the immune system to prevent and treat disease Approved Prophylactic Vaccine repaiwseie) —« Preevbrio™™ vr A LN Prophylactic Candidates Cytomegalovirus (CMV) —_VBF-1501 evo [I COVID-19 (Ancestral) VBI-2902 (monovale

  6. Slide 6: Notable Recent Accomplishments Prepare VBI for a Transformative 2023

    Slide 6: Notable Recent Accomplishments Prepare VBI for a Transformative 2023

    Notable Recent Accomplishments Prepare VBI for a Transformative 2023 First US, EU, & Canadian Approval Advancement & Expansion of Pipeline wm, VCD) 8 Financial | ms O} Strong Financia + PreHevbrio™ (Hepatitis 8 Vaccine [Recombinant]) approved by the FDA in Nov. 2021, added to the ACIP list of recomm

  7. Slide 7: PreHevbrio Hepatitis B Vaccine (Recombinant)

    Slide 7: PreHevbrio Hepatitis B Vaccine (Recombinant)

    VU PreHevbrio Hepatitis B Vaccine (Recombinant)

  8. Slide 8: PreHevbrio is the Only 3-Antigen HBV Vaccine

    Slide 8: PreHevbrio is the Only 3-Antigen HBV Vaccine

    PreHevbrio is the Only 3-Antigen HBV Vaccine PreHevbrio is scientifically differentiated from other HBV vaccines — expressing the three a B surface antigens (S, pre-SI, and pre-S2), and manufactured in mammalian cells (vs. yeast! PreHevbrio: ze Pre-Sl Antigen @o The pre-SI and pre-S2 regions of the

  9. Slide 9: More Adults Achieved Seroprotection with PreHevbrio in Phase 3 Studies

    Slide 9: More Adults Achieved Seroprotection with PreHevbrio in Phase 3 Studies

    More Adults Achieved Seroprotection with PreHevbrio in Phase 3 Studies PROTECT Phase 3 Study CONSTANT Phase 3 Study 2-arm safety and immunogenicity study N=1607 aduits aged 18-90 years ‘Seroprotection Rate! (SPR) 4 Weeks After Receiving the 3% Dose of PreHevbrio or Engerix-B @ Pretievorio @ Engerix-

  10. Slide 10: Hepatitis B Remains a Persistent Public Health Problem

    Slide 10: Hepatitis B Remains a Persistent Public Health Problem

    Hepatitis B Remains a Persistent Public Health Problem —— U.S. & Europe : HBV Disease Burden and Challenges HBV infection is the most common blood-borne infection, with an estimated 240M- 350M chronically-infected individuals worldwide Suboptimal surveillance results in under-representation of true

  11. Slide 11: Public Health Bodies are Changing Tactics

    Slide 11: Public Health Bodies are Changing Tactics

    Public Health Bodies are Changing Tactics, Bringing Renewed Prioritization in the Fight to Eliminate HBV Changing U.S. Adult HBV Vaccination Guidelines * In November 2021, the CDC’s Advisory Committee on Immunization Practices (ACIP) unanimously voted to move from a risk-based HBV adult vaccination

  12. Slide 12: Commercialization & Upcoming Milestones

    Slide 12: Commercialization & Upcoming Milestones

    Commercialization & Upcoming Milestones Commercialization Partnerships : Cc + vBl entered into a full end-to-end commercialization partnership with Syneos Health in 2019 to support the US. Syn eos launch of PreHevbrio™, including VBI-dedicated leadership, medical, market access, cind sales teams Hea

  13. Slide 13: Hepatitis B (HBV) Therapeutic Candidate: VBI-2601

    Slide 13: Hepatitis B (HBV) Therapeutic Candidate: VBI-2601

    IW zB BS = (Hepatitis B (HBV) \) Therapeutic Candidate : VBI-2601 B

  14. Slide 14: Current Chronic Hepatitis B Landscape

    Slide 14: Current Chronic Hepatitis B Landscape

    Current Chronic Hepatitis B Landscape Chronic HBV infection represents a critical unmet public health need and an opportunity for meaningful innovation to achieve a functional cure Global chronic HBV (cHBV) unmet need: + Over 290 million adults + Nucleotide/nucleoside estimated to be infected revers

  15. Slide 15: VBI-2601: Potential to be a Critical Component of a Functional Cure

    Slide 15: VBI-2601: Potential to be a Critical Component of a Functional Cure

    VBI-2601 : Potential to be a Critical Component of a Functional Cure for Chronic HBV Infection Scientific consensus is that a functional cure for HBV is within reach, but will likely require the use of an immunotherapeutic as part of a combination approach A functional cure will likely require the a

  16. Slide 16: VBI-2601 Development Plan & Status

    Slide 16: VBI-2601 Development Plan & Status

    VBI-2601 Development Plan & Status Studies designed & executed in partnership with Brii Biosciences Phase Ib/2a Study Completed in 2021 + Two-part, multi-center, controlled, dose-escalation study (n=44) + Assessed VBI-2601 safety, tolerability, and immunologic antiviral activity in non-cirrhotic pat

  17. Slide 17: Proof of Mechanism: Significant Restoration of Antibody and T Cell Responses

    Slide 17: Proof of Mechanism: Significant Restoration of Antibody and T Cell Responses

    Proof of Mechanism : Significant Restoration of Antibody and T Cell Responses Demonstrated in Phase 1b/2a Study Complete dataset announced at the International Liver Congress 2021 Potent re-stimulation of T cell responses to HBV surface antigens (S, Pre-SI, Pre-S2) seen in 67% (Cohort B n=6/9) and 7

  18. Slide 18: Phase 2 Combination Study: Design

    Slide 18: Phase 2 Combination Study: Design

    Phase 2 Combination Study : Design n=50 adult, non-cirrhotic patients who received 2 12 months NRTI treatment were randomized across 3 cohorts 00 04 08 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 4 Week NRT! Discontinuation Monitorng® eooeceeee 6 Follow Up ooecee eee eoeoeevoee

  19. Slide 19: Phase 2 Combination Study: Patient Demographics

    Slide 19: Phase 2 Combination Study: Patient Demographics

    Phase 2 Combination Study : Patient Demographics ev “a eo Bre Cohort A Cohort C e Mean Age + SD (years) 459+105 476 +9) 453495 Male, n (%) 8 (72.7%) 14 (70.0%) 15 (75.0%) Race, n (%) Asian m1 (100%) 18 (90%) 18 (90.0%) Black or African American ® 2 (10.0%) 1(8.0%) White 0 fe) 1(5.0%) HBeAg Status at

  20. Slide 20: VBI-2601 Well Tolerated in Both Combination Cohorts

    Slide 20: VBI-2601 Well Tolerated in Both Combination Cohorts

    VBI-2601 Well Tolerated in Both Combination Cohorts ‘Cohort © ‘Any TEAES 10 (100%) 19 (950%) 20 (100%) Grade 1 TEES 10 (100%) 19 (950%) 17 (850%) ‘Grads 2 TEAES 1(00%) 7 (50%) 6 (80.0%) 2 Grade 3 TEAES o ° 2 (10.0%) BRI-835 Related TEAES 7 (700%) 13 (650%) 10 (500%) + Majority of TEAEs were Grade |

  21. Slide 21: Notable Reductions in S Antigen Seen Across Cohorts

    Slide 21: Notable Reductions in S Antigen Seen Across Cohorts

    Notable Reductions in S Antigen Seen Across Cohorts Mean (Sb) Change From Baseline (logo U/ml) Week 32 Week 40 z z 2 (siRNA EOT) (Combo E0T) ES 2 g “175 2 & 3 (039) i i i = ere * * * “181 “77 (om) (072) o 8 «© mm a Study Week study Week Basoline HBsAg: 387.3 IU/mL Baseline HBsAg : 6947 1U/ml Baselin

  22. Slide 22: VBI-2601 + siRNA Combination Elicited Robust Restoration of HBV Surface Antibodies

    Slide 22: VBI-2601 + siRNA Combination Elicited Robust Restoration of HBV Surface Antibodies

    VBI-2601 + siRNA (BRII-835) Combination Elicited Robust Restoration of HBV Surface Antibodies ant IU/L, <21UIL, 2sX<10 IU/L, 10X<100 IU/L 100<X<1000 IU/L. 21000 IU/L Number of participants with anti-HBs titers by W40 High antibody titers 2 10 IU/L induced in 50% (Cohort B pe) ‘and 58% (Cohort C n=I1

  23. Slide 23: VBI-2601 + siRNA Combination Induced Strong S Antigen-Specific T-Cell Responses

    Slide 23: VBI-2601 + siRNA Combination Induced Strong S Antigen-Specific T-Cell Responses

    VBI-2601 + siRNA Combination Induced Strong S Antigen-Specific T-Cell Responses VBI-2601 with or without co-adjuvant IFN-a generated notable improvements in HBV S Antigen (HBsAg)-specific T-Cell responses compared to siRNA alone T-Cell Response n=7/10_n=7/10 Addition of VBI-2601 in treatment regimen

  24. Slide 24: S Antigen Reductions to LLOQ or Below Achieved in Two Patients

    Slide 24: S Antigen Reductions to LLOQ or Below Achieved in Two Patients

    S Antigen Reductions to LLOQ or Below, to an Undetectable Level, Achieved in Two Patients Robust HBV-specific antibody and T-cell responses associated with $ Antigen (HBsAg) reduction observed in both patients Patient 1 (Cohort 8) Patient 2 (Cohort C) Baseline HBsAg : 723 1U/mL. Baseline HBsAg : 776

  25. Slide 25: VBI-2601 Ongoing Partnership & Upcoming Milestones

    Slide 25: VBI-2601 Ongoing Partnership & Upcoming Milestones

    VBI-2601 Ongoing Partnership & Upcoming Milestones Brii Partnership: + In December 2018, VBI announced a license and collaboration agreement with Brii Biosciences (Brii Bio) to develop a functional cure for Hepatitis B + Upfront : SIIM - $4M upfront payment + $7M equity investment Bri Biosciences +

  26. Slide 26: Coronaviruses

    Slide 26: Coronaviruses

    3 Coronaviruses 26

  27. Slide 27: The Virus that Causes COVID-19 Continues to Evolve

    Slide 27: The Virus that Causes COVID-19 Continues to Evolve

    The Virus that Causes COVID-19 Continues to Evolve, Leading to Increasing Number of Mutations and Variants of Concerns COVID-19 Astrain of coronavirus first identified in December 2019 in Wuhan, China Since then, as of February 2023, there have been ~675M confirmed cases worldwide, responsible for 6

  28. Slide 28: VBI is Committed to the Long-Term Protection Against Coronaviruses

    Slide 28: VBI is Committed to the Long-Term Protection Against Coronaviruses

    VBI is Committed to the Long-Term Protection Against Coronaviruses vBI's coronavirus pipeline program (VBI-2900) is designed with the goal of eliciting broad and durable immune responses against COVID-19 and coronaviruses VBI-2901 Trivalent Pan-Coronavirus VBI-2902 Monovatent COVID-I9 VBI-2905 Monov

  29. Slide 29: VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines

    Slide 29: VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines

    In Phase la Clinical Study, VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines After two doses of 5ug, VBI-2902a elicited neutralizing antibody (nAb) responses 4.3X higher than a panel of convalescent sera, without the use of a next-generation adjuvant Neutralizing Activity’ C

  30. Slide 30: Trivalent VBI-2901 Induced Robust Antibody and Neutralizing Titers

    Slide 30: Trivalent VBI-2901 Induced Robust Antibody and Neutralizing Titers

    Trivalent VBI-2901 Induced Robust Antibody and Neutralizing Titers Against an Extended Panel of Variants VBI-2901 induced higher and more consistent immunogenicity against Beta, Delta, Kappa, and Lambda variants, with evidence for broadening immunity rather than just boosting cross-reactive antibodi

  31. Slide 31: VBI-2900 Program Summary & Next Steps

    Slide 31: VBI-2900 Program Summary & Next Steps

    VBI-2900 Program Summary & Next Steps eVIP Benefits Y strong immune responses when compared to standard recombinants Y — Multivalency allows for broadly reactive vaccines VY Highly potent immunogenicity, comparable to licensed vaccines Proof-of-Concept Data VY towelinical doses (Sug) & no requiremen

  32. Slide 32: Glioblastoma (GBM)

    Slide 32: Glioblastoma (GBM)

    > § Glioblastoma (GBM)

  33. Slide 33: Unique Approach to Immuno-Oncology

    Slide 33: Unique Approach to Immuno-Oncology

    Unique Approach to Immuno-Oncology CMV as a Foreign Viral Antigen + 90% of some solid tumors, including glioblastoma (GBM), breast cancers’, and medulloblastomas? are CMV+ tumors + CMVis not causative, but can influence disease progression of CMV+ tumors + Because CMV is so broadly (and differential

  34. Slide 34: Phase 1/2a Study Design & Objectives

    Slide 34: Phase 1/2a Study Design & Objectives

    Phase 1/2a Study Design & Objectives Two-part, open-label, dose escalation study designed to assess the safety, tolerability, and optimal therapeutic dose level of VBI-1901 in recurrent GBM patients Phase 1 (Part A) : Dose Study Arm 1: Low Dose (n=6) + Enrollment completed December 2018 (n=18) 0.4ug

  35. Slide 35: Tumor Responses Translated to Clinical Benefit in Phase 1/2a High-Dose Cohorts

    Slide 35: Tumor Responses Translated to Clinical Benefit in Phase 1/2a High-Dose Cohorts

    Tumor Responses Translated to Clinical Benefit in Phase 1/2a High-Dose Cohorts Based upon these rGBM data, U.S. FDA granted Fast Track Designation in June 2021 for VBI-1901 + GM-CSF for the treatment of recurrent GBM patients with first tumor recurrence Tumor Responses 10110ug + GMCs rt A + Part B)

  36. Slide 36: VBI-1901 Unmet Need & Upcoming Milestones

    Slide 36: VBI-1901 Unmet Need & Upcoming Milestones

    VBI-1901 Unmet Need & Upcoming Milestones GBM Represents a Significant Unmet Medical Need: GBM is the most common primary brain cancer with approximately 14,000 annual diagnoses in the US, and a low median overall survival of 15-18 months after initial diagnosis! There is no standard of care in the

  37. Slide 37: 37

    Slide 37: 37

    37

  38. Slide 38: VBI Team

    Slide 38: VBI Team

    VBI Team —Management JES ¢ fe Jott Boxter David E. Anderson, Francisco Diaz-Mitoma, Christopher McNulty Nell Beattio John Dillman Avi Mazaltov President & CEO PhD. MD, PhO. Chief Financial Officer Chief Business Officer Chief Commercial Global Head of Chief Scientific Officer Chief Medical Officer.

  39. Slide 39: VBI Vaccines Global Footprint

    Slide 39: VBI Vaccines Global Footprint

    VBI Vaccines Global Footprint Ottawa, Canada Research Operations R&D headquarters and facility Rehovot, Israel Manufacturing Facility GMP manufacturing facility for the production of the HBV program candidates Cambridge, MA, USA *——— Corporate Headquarters Central location in biotechnology hub rd .

  40. Slide 40: Summary of Anticipated Upcoming Milestones

    Slide 40: Summary of Anticipated Upcoming Milestones

    Summary of Anticipated Upcoming Milestones Px HBV PreHevbrio (US.) Tx HBV vel-2601 Coronaviruses VBI-290) GBM vel-190} HI 2028 : Following European Commission and UK Medicines and Healthcare products Regulatory Agency (MHRA) approvals, VBI expects to make PreHevbri available in certain European coun

  41. Slide 41: VBI Vaccines Inc.

    Slide 41: VBI Vaccines Inc.

    VBI Vaccines Inc. WW < w Ui Zz S NS Y www.vbivaccines.com

Source: SEC EDGAR · 8-K filed Feb 28, 2023

More decks from VBI Vaccines Inc.